New drug revealed that eases and suppresses common metabolic disorders
Osteoporosis is a common metabolic disorder and it remains one of the most neglected diseases as the devastating consequences of its development can be drastically improved by targeted molecular therapy. However for all intents and purposes the most interesting aspect of our endeavor were the two research groups simultaneous efforts spearheaded by Prof. Weihong Ma and Dr. Ramil Gorani from the Laboratory of Pharmaceutical Analysis and Drug Design of the National Science Foundation Centre of Excellence for Drug Design Regulatory Analysis and Commercialization (TRANSCARE) of Chinese Academy of Sciences (CAS) to discover a new drug that is capable of reducing the progression of two nephroblastologic disorders at embryonic and neonatal stages without compromising its other absorption parameters.
Osteoporosis is a common metabolic disorder(…)
Osteoporosis is considered a common disease and even more prevalent in underdeveloped countries. People with osteoporosis are usually older than average and thus almost exclusively susceptible to it. There are virtually no clinical trials to protect against or cure the disease today as the clinical manifestation of the disease is mainly driven by chronic exposure to harmful but apparently untreated oxygen levels.
The two most common diseases with osteoporosis are identified by the presence of a residue of fibroblast growth factor (FGF) in the mitochondria the cell energy suppliers. FGFs stimulate the production of toxic lipids but they also have the capability of controlling cell growth. In the case of osteoporosis the mice bearing a mutated FGF gene have a phenotype resembling that of infact:
As the above-mentioned treatments have been shown to have limited efficacy or even can lead to adverse effects in these animals it is considered that these drugs shouldnt be approved for human use until at least 2030. Hence at the beginning of 2019 BASMAs scientists led the research teams responsible for discovering a new therapeutic option against the two disorders discussed above. At the same time they conducted clinical trials of this new drug (methotrexate and rosiglitazone) in mice when the drug(…)
technically is used in combination with beta-blockers and metformin. Other crucial following indications from studies with mouse models of osteoporosis and in part-human clinical trials for osteoporosis are being studied in human patients.
Andru — induced bone growth without hematopoiesis or osteolytic bone infections — now made a major contribution to the field of translational medicine.